Advertisement
Advertisement

TRVI

TRVI logo

Trevi Therapeutics, Inc. Common Stock

14.50
USD
Sponsored
+0.45
+3.20%
May 08, 16:00 UTC -4
Closed
exchange

Pre-Market

14.27

-0.23
-1.59%

Trevi Therapeutics, Inc. Common Stock Profile

About

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut.

Info & Links

CEO

Jennifer L. Good

Headquarters

195 CHURCH STREET, 16TH FLOOR
NEW HAVEN, CT 06510, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.trevitherapeutics.com

Auditor

Ernst & Young LLP

Share holders

17

Employees

34

Trevi Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

2.03B

Enterprise Value

2.01B

Enterprise Value/EBITDA(ttm)

-40.81

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

9.31

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-25.49%

Return on Invested Capital(ttm)

-27.35%

Return on Assets(ttm)

-24.15%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-49.18M

Net Income Available to Common(ttm)

-42.76M

Diluted EPS(ttm)

-0.32

Share Statistics

Beta (5Y Monthly)

0.99

52-Week Change

119.70%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

128.40M

Dividend Yield

0.00%

Float4

104.90M

% Held by Insiders

18.30%

% Held by Institutions

95.76%

Balance Sheet

Total Cash(mrq)

188.26M

Total Cash Per Share(mrq)

1.47

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

19.66%

Quick Ratio(mrq)

19.66%

Book Value Per Share(mrq)

1.43

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.31

Free Cash Flow(ytd)

-42.10M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement